Single-dose, first-in-human study of AMG 853: Pharmacokinetics, pharmacodynamics, and safety in healthy adults
C. Banfield, J. Parnes, M. Emery, L. Ni, N. Zhang, P. Hodsman (Thousand Oaks, Seattle, United States Of America; Melbourne, Australia)
Source: Annual Congress 2010 - New treatments for asthma and COPD
Session: New treatments for asthma and COPD
Session type: Thematic Poster Session
Number: 1164
Disease area: Airway diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
C. Banfield, J. Parnes, M. Emery, L. Ni, N. Zhang, P. Hodsman (Thousand Oaks, Seattle, United States Of America; Melbourne, Australia). Single-dose, first-in-human study of AMG 853: Pharmacokinetics, pharmacodynamics, and safety in healthy adults. Eur Respir J 2010; 36: Suppl. 54, 1164
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you:
Single-dose, first-in-human study of AMG 317: safety and pharmacokinetics in healthy and asthmatic adults Source: Annual Congress 2008 - New treatments for asthma Year: 2008
Multiple-dose study of AMG 853 in healthy adults: Safety and pharmacokinetics Source: Annual Congress 2010 - New treatments for asthma and COPD Year: 2010
Multiple-dose study of AMG 317 in adults with asthma: pharmacokinetics and safety Source: Annual Congress 2008 - New treatments for asthma Year: 2008
Roflumilast and sildenafil in healthy male volunteers: Single-dose pharmacokinetic interactions, safety and tolerability Source: Annual Congress 2010 - Drug delivery and pharmacokinetics II Year: 2010
Safety, pharmacokinetics and pharmacodynamics of BI 1323495 in healthy males Source: Virtual Congress 2020 – Scientific advances in airway pharmacology Year: 2020
Safety, pharmacokinetics, and pharmacodynamics of TD-8236, an inhaled pan-JAK inhibitor, following single- and multiple-ascending doses in healthy volunteers and mild asthmatics Source: Virtual Congress 2021 – Clinical trials in airway diseases: novel treatments and new evidence Year: 2021
Safety, tolerability, pharmacodynamics (PD) and pharmacokinetics (PK) of GSK573719 inhalation powder in healthy subjects Source: Annual Congress 2011 - Drug delivery and pharmacokinetics II Year: 2011
Evaluation of safety, tolerability, pharmacokinetics, and food effect of Danirixin oral tablets in Japanese elderly healthy subjects Source: International Congress 2018 – Integrating pharmacological and non-pharmacological management in COPD: are we there yet? Year: 2018
Safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of AZD7594 after single and multiple ascending inhaled doses in healthy Japanese males Source: International Congress 2017 – COPD management Year: 2017
A phase 1, single-center, open-label, dose-rising clinical trial to evaluate the pharmacokinetics, safety and tolerability of treprostinil inhalation powder (TreT) in healthy normal volunteers Source: International Congress 2019 – Pulmonary hypertension: clinical Year: 2019
INTEGRIS-IPF: a 12-week, Phase 2a study evaluating the safety, tolerability and pharmacokinetics of PLN-74809 in participants with IPF Source: Virtual Congress 2020 – News on diagnosis and therapy of idiopathic pulmonary fibrosis Year: 2020
The safety, tolerability and pharmacokinetics of AZD5069, a novel CXCR2 antagonist, in healthy Japanese volunteers Source: Annual Congress 2012 - The best of pharmacology treatment for asthma and COPD Year: 2012
Pharmacokinetics and pharmacodynamics of ciclesonide and its active principle after inhalative and intravenous administration in healthy subjects Source: Eur Respir J 2002; 20: Suppl. 38, 110s Year: 2002
A randomized, crossover study to examine the pharmacodynamics and safety of a new antimuscarinic (TD-4208) in COPD Source: Annual Congress 2012 - Trials in COPD: novel treatments and insights Year: 2012
A comparative study of the safety, tolerability, pharmacodynamics (PD) and pharmacokinetics (PK) of salmeterol HFA and CFC MDI inhalers in healthy subjects Source: Eur Respir J 2004; 24: Suppl. 48, 582s Year: 2004
Safety, tolerability and pharmacokinetics (PK) of AZD8154 (a selective PI3K?d inhibitor) after single ascending inhaled doses in healthy volunteers Source: International Congress 2019 – Airway inflammation: pharmacological mechanisms and novel targets Year: 2019
Rising single-dose safety and pharmacokinetics of oral SCH 527123, a novel antagonist of CSCR2, in healthy volunteers Source: Annual Congress 2007 - New insights into the treatment of COPD Year: 2007
The novel elastase inhibitor BAY 85-8501: First-in-man study to evaluate safety, tolerability and pharmacokinetics in healthy male subjects Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014
Dry powder inhaled ribavirin in healthy volunteers: safety, tolerability, lung and systemic pharmacokinetics Source: International Congress 2017 – From microbiology to clinical work Year: 2017
Safety and tolerability of single doses of AZD5069 in healthy volunteers Source: Annual Congress 2011 - Drug delivery and pharmacokinetics II Year: 2011